Medical abortion with oral methotrexate and vaginal misoprostol

Obstetrics and Gynecology

Volumn 90, Issue 4, 1997, Pages 611-616

  Creinin, Mitchell D ^a,b,c,d,e   Vittinghoff, Eric ^a,b,c,d,e   Schaff, Eric ^a,b,c,d,e   Klaisle, Cynthia ^a,b,c,d,e   Darney, Philip D ^a,b,c,d,e   Dean, Catherine ^a,b,c,d,e  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^d SAN FRANCISCO GENERAL HOSPITAL   (United States)

^e WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METHOTREXATE; MISOPROSTOL;

ADULT; ARTICLE; CHILL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; FEMALE; HUMAN; INDUCED ABORTION; INTRAVAGINAL DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NAUSEA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT OUTCOME; VAGINA BLEEDING; VOMITING;

ABORTIFACIENT AGENTS, NONSTEROIDAL; ABORTION, INDUCED; ADMINISTRATION, INTRAVAGINAL; ADMINISTRATION, ORAL; ADULT; CONFIDENCE INTERVALS; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; METHOTREXATE; MISOPROSTOL; MULTIVARIATE ANALYSIS; PROSPECTIVE STUDIES; REGRESSION ANALYSIS;

EID: 0030964730     PISSN: 00297844     EISSN: 1873233X     Source Type: Journal    
DOI: 10.1016/S0029-7844(97)00266-4     Document Type: Article

References (16)

1. Creinin MD, Vittinghoff E, Keder L, Damey PD, Tiller G. Methotrexate and misoprostol for early abortion: A multicenter trial. I. Safety and acceptability. Contraception 1996;53:321-7.
2. Creinin MD. Oral methotrexate and vaginal misoprostol for early abortion. Contraception 1996;54:15-8.
3. Office of Occupational Medicine, Directorate of Technical Support, Occupational Safety and Health Administration, US Department of Labor. Work practice guidelines for personnel dealing with cytotoxic (antineoplastic) drugs. OSHA instruction publication 8-1.1. Washington, DC: OSHA, 1986 Jan 29.
4. Furst DE. Practical clinical pharmacology and drug interactions of low-dose methotrexate therapy in rheumatoid arthritis. Br J Rheumatol 1995;34(suppl):20-5.
5. Jundt JW, Browne BA, Fiocco GP, Steele AD, Mock D. A comparison of low dose methotrexate bioavailability: Oral solution, oral tablet, subcutaneous and intramuscular dosing. J Rheumatol 1993; 20:1845-9.
6. Oguey D, Kõlliker F, Gerber NJ, Reichen J. Effect of food on the bioavailability of low-dose methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 1992;35:611-4.
7. Henderson ES, Adamson RH, Oliverio VT. The metabolic fate of titrated methotrexate. II. Absorption and excretion in man. Cancer Res 1965;25:1018-24.
8. Halprin KM, Fukui K, Ohkawara A. Blood levels of methotrexate and the treatment of psoriasis. Arch Dermatol 1971;103:243-9.
9. Goldstein S. Embryonic ultrasonographic measurements: Crown rump length revisited. Am J Obstet Gynecol 1991;165:497-501.
10. Creinin MD, Darney PD. Methotrexate and misoprostol for early abortion. Contraception 1993;48:339-48.
11. Creinin MD, Vittinghoff E, Galbraith S, Klaisle C. Methotrexate and misoprostol for early abortion: A randomized trial comparing misoprostol 3 days and 7 days following methotrexate. Am J Obstet Gynecol 1995;173:1578-84.
12. DiSaia PJ, Creasman WT. Clinical gynecologic oncology. St. Louis: CV Mosby, 1989:378.
13. Lemeshow S, Hosmer DW. Applied logistic regression. New York: John Wiley & Sons, 1989.
14. Creinin MD, Vittinghoff E. Methotrexate and misoprostol versus misoprostol alone for early abortion: A randomized controlled trial. JAMA 1994;272:1190-5.
15. Creinin MD. Methotrexate for abortion at 42 days’ gestation. Contraception 1993;48:519-25.
16. Creinin MD. Methotrexate and misoprostol for abortion at 57-63 days gestation. Contraception 1994;50:511-5.